Identification of SARS-COV spike protein-derived and HLA-A2-restricted human CTL epitopes by using a new muramyl dipeptidederivative adjuvant.
Identifieur interne : 000679 ( PubMed/Curation ); précédent : 000678; suivant : 000680Identification of SARS-COV spike protein-derived and HLA-A2-restricted human CTL epitopes by using a new muramyl dipeptidederivative adjuvant.
Auteurs : Y-Z Chen [Japon] ; G. Liu ; S. Senju ; Q. Wang ; A. Irie ; M. Haruta ; M. Matsui ; F. Yasui ; M. Kohara ; Y. NishimuraSource :
- International journal of immunopathology and pharmacology [ 0394-6320 ]
Descripteurs français
- KwdFr :
- Acétylmuramyl alanyl isoglutamine (analogues et dérivés), Adjuvants immunologiques (pharmacologie), Animaux, Antigène HLA-A2 (immunologie), Antigènes viraux (immunologie), Déterminants antigéniques des lymphocytes T, Glycoprotéine de spicule des coronavirus, Glycoprotéines membranaires (immunologie), Humains, Immunisation, Lymphocytes T cytotoxiques (immunologie), Protéines de l'enveloppe virale (immunologie), Présentation d'antigène, Souris, Souris de lignée C57BL, Souris transgéniques, Vaccins antiviraux (immunologie).
- MESH :
- analogues et dérivés : Acétylmuramyl alanyl isoglutamine.
- immunologie : Antigène HLA-A2, Antigènes viraux, Glycoprotéines membranaires, Lymphocytes T cytotoxiques, Protéines de l'enveloppe virale, Vaccins antiviraux.
- pharmacologie : Adjuvants immunologiques.
- Animaux, Déterminants antigéniques des lymphocytes T, Glycoprotéine de spicule des coronavirus, Humains, Immunisation, Présentation d'antigène, Souris, Souris de lignée C57BL, Souris transgéniques.
English descriptors
- KwdEn :
- Acetylmuramyl-Alanyl-Isoglutamine (analogs & derivatives), Adjuvants, Immunologic (pharmacology), Animals, Antigen Presentation, Antigens, Viral (immunology), Epitopes, T-Lymphocyte, HLA-A2 Antigen (immunology), Humans, Immunization, Membrane Glycoproteins (immunology), Mice, Mice, Inbred C57BL, Mice, Transgenic, Spike Glycoprotein, Coronavirus, T-Lymphocytes, Cytotoxic (immunology), Viral Envelope Proteins (immunology), Viral Vaccines (immunology).
- MESH :
- chemical , analogs & derivatives : Acetylmuramyl-Alanyl-Isoglutamine.
- chemical , immunology : Antigens, Viral, HLA-A2 Antigen, Membrane Glycoproteins, Viral Envelope Proteins, Viral Vaccines.
- chemical , pharmacology : Adjuvants, Immunologic.
- immunology : T-Lymphocytes, Cytotoxic.
- Animals, Antigen Presentation, Epitopes, T-Lymphocyte, Humans, Immunization, Mice, Mice, Inbred C57BL, Mice, Transgenic, Spike Glycoprotein, Coronavirus.
Abstract
Severe acute respiratory syndrome (SARS) spread during the winter of 2003, and attempts have been made to develop vaccines against SARS corona virus (SARS-CoV). The present study provides a strategy to rapidly identify SARS-CoV-derived antigenic peptides recognized by HLA-A2-restricted cytotoxic T lymphocytes (CTLs). Forty-three candidate peptides having HLA-A2-binding motifs were selected in silico and HLA-A2/Db chimeric MHC class I-transgenic mice were immunized with these peptides and a new derivative of muramyl dipeptide that can induce upregulation of HLA-DR, CD80, CD86, and CD40 in human CD14+ antigen presenting cells, was administered as an adjuvant. Six HLAA2-restricted mouse CTL epitopes were identified, including two new epitopes which have never been reported before. One of the novel peptides was naturally processed and successfully induced HLAA2-restricted specific CTLs in both HLA transgenic mice and healthy donors. The method was useful, convenient and efficient for rapid identification of CTL epitopes derived from SARS-CoV proteins and will be possibly applicable for other pathogens to develop a peptide-based vaccine.
DOI: 10.1177/039463201002300115
PubMed: 20378004
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000679
Links to Exploration step
pubmed:20378004Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Identification of SARS-COV spike protein-derived and HLA-A2-restricted human CTL epitopes by using a new muramyl dipeptidederivative adjuvant.</title><author><name sortKey="Chen, Y Z" sort="Chen, Y Z" uniqKey="Chen Y" first="Y-Z" last="Chen">Y-Z Chen</name><affiliation wicri:level="1"><nlm:affiliation>Department of Immunogenetics, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Immunogenetics, Graduate School of Medical Sciences, Kumamoto University, Kumamoto</wicri:regionArea></affiliation></author><author><name sortKey="Liu, G" sort="Liu, G" uniqKey="Liu G" first="G" last="Liu">G. Liu</name></author><author><name sortKey="Senju, S" sort="Senju, S" uniqKey="Senju S" first="S" last="Senju">S. Senju</name></author><author><name sortKey="Wang, Q" sort="Wang, Q" uniqKey="Wang Q" first="Q" last="Wang">Q. Wang</name></author><author><name sortKey="Irie, A" sort="Irie, A" uniqKey="Irie A" first="A" last="Irie">A. Irie</name></author><author><name sortKey="Haruta, M" sort="Haruta, M" uniqKey="Haruta M" first="M" last="Haruta">M. Haruta</name></author><author><name sortKey="Matsui, M" sort="Matsui, M" uniqKey="Matsui M" first="M" last="Matsui">M. Matsui</name></author><author><name sortKey="Yasui, F" sort="Yasui, F" uniqKey="Yasui F" first="F" last="Yasui">F. Yasui</name></author><author><name sortKey="Kohara, M" sort="Kohara, M" uniqKey="Kohara M" first="M" last="Kohara">M. Kohara</name></author><author><name sortKey="Nishimura, Y" sort="Nishimura, Y" uniqKey="Nishimura Y" first="Y" last="Nishimura">Y. Nishimura</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="????"><PubDate><MedlineDate>2010 Jan-Mar</MedlineDate></PubDate></date><idno type="RBID">pubmed:20378004</idno><idno type="pmid">20378004</idno><idno type="doi">10.1177/039463201002300115</idno><idno type="wicri:Area/PubMed/Corpus">000679</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000679</idno><idno type="wicri:Area/PubMed/Curation">000679</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000679</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Identification of SARS-COV spike protein-derived and HLA-A2-restricted human CTL epitopes by using a new muramyl dipeptidederivative adjuvant.</title><author><name sortKey="Chen, Y Z" sort="Chen, Y Z" uniqKey="Chen Y" first="Y-Z" last="Chen">Y-Z Chen</name><affiliation wicri:level="1"><nlm:affiliation>Department of Immunogenetics, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Immunogenetics, Graduate School of Medical Sciences, Kumamoto University, Kumamoto</wicri:regionArea></affiliation></author><author><name sortKey="Liu, G" sort="Liu, G" uniqKey="Liu G" first="G" last="Liu">G. Liu</name></author><author><name sortKey="Senju, S" sort="Senju, S" uniqKey="Senju S" first="S" last="Senju">S. Senju</name></author><author><name sortKey="Wang, Q" sort="Wang, Q" uniqKey="Wang Q" first="Q" last="Wang">Q. Wang</name></author><author><name sortKey="Irie, A" sort="Irie, A" uniqKey="Irie A" first="A" last="Irie">A. Irie</name></author><author><name sortKey="Haruta, M" sort="Haruta, M" uniqKey="Haruta M" first="M" last="Haruta">M. Haruta</name></author><author><name sortKey="Matsui, M" sort="Matsui, M" uniqKey="Matsui M" first="M" last="Matsui">M. Matsui</name></author><author><name sortKey="Yasui, F" sort="Yasui, F" uniqKey="Yasui F" first="F" last="Yasui">F. Yasui</name></author><author><name sortKey="Kohara, M" sort="Kohara, M" uniqKey="Kohara M" first="M" last="Kohara">M. Kohara</name></author><author><name sortKey="Nishimura, Y" sort="Nishimura, Y" uniqKey="Nishimura Y" first="Y" last="Nishimura">Y. Nishimura</name></author></analytic><series><title level="j">International journal of immunopathology and pharmacology</title><idno type="ISSN">0394-6320</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acetylmuramyl-Alanyl-Isoglutamine (analogs & derivatives)</term><term>Adjuvants, Immunologic (pharmacology)</term><term>Animals</term><term>Antigen Presentation</term><term>Antigens, Viral (immunology)</term><term>Epitopes, T-Lymphocyte</term><term>HLA-A2 Antigen (immunology)</term><term>Humans</term><term>Immunization</term><term>Membrane Glycoproteins (immunology)</term><term>Mice</term><term>Mice, Inbred C57BL</term><term>Mice, Transgenic</term><term>Spike Glycoprotein, Coronavirus</term><term>T-Lymphocytes, Cytotoxic (immunology)</term><term>Viral Envelope Proteins (immunology)</term><term>Viral Vaccines (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Acétylmuramyl alanyl isoglutamine (analogues et dérivés)</term><term>Adjuvants immunologiques (pharmacologie)</term><term>Animaux</term><term>Antigène HLA-A2 (immunologie)</term><term>Antigènes viraux (immunologie)</term><term>Déterminants antigéniques des lymphocytes T</term><term>Glycoprotéine de spicule des coronavirus</term><term>Glycoprotéines membranaires (immunologie)</term><term>Humains</term><term>Immunisation</term><term>Lymphocytes T cytotoxiques (immunologie)</term><term>Protéines de l'enveloppe virale (immunologie)</term><term>Présentation d'antigène</term><term>Souris</term><term>Souris de lignée C57BL</term><term>Souris transgéniques</term><term>Vaccins antiviraux (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Acetylmuramyl-Alanyl-Isoglutamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antigens, Viral</term><term>HLA-A2 Antigen</term><term>Membrane Glycoproteins</term><term>Viral Envelope Proteins</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Adjuvants, Immunologic</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Acétylmuramyl alanyl isoglutamine</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Antigène HLA-A2</term><term>Antigènes viraux</term><term>Glycoprotéines membranaires</term><term>Lymphocytes T cytotoxiques</term><term>Protéines de l'enveloppe virale</term><term>Vaccins antiviraux</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>T-Lymphocytes, Cytotoxic</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Adjuvants immunologiques</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Antigen Presentation</term><term>Epitopes, T-Lymphocyte</term><term>Humans</term><term>Immunization</term><term>Mice</term><term>Mice, Inbred C57BL</term><term>Mice, Transgenic</term><term>Spike Glycoprotein, Coronavirus</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Déterminants antigéniques des lymphocytes T</term><term>Glycoprotéine de spicule des coronavirus</term><term>Humains</term><term>Immunisation</term><term>Présentation d'antigène</term><term>Souris</term><term>Souris de lignée C57BL</term><term>Souris transgéniques</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS) spread during the winter of 2003, and attempts have been made to develop vaccines against SARS corona virus (SARS-CoV). The present study provides a strategy to rapidly identify SARS-CoV-derived antigenic peptides recognized by HLA-A2-restricted cytotoxic T lymphocytes (CTLs). Forty-three candidate peptides having HLA-A2-binding motifs were selected in silico and HLA-A2/Db chimeric MHC class I-transgenic mice were immunized with these peptides and a new derivative of muramyl dipeptide that can induce upregulation of HLA-DR, CD80, CD86, and CD40 in human CD14+ antigen presenting cells, was administered as an adjuvant. Six HLAA2-restricted mouse CTL epitopes were identified, including two new epitopes which have never been reported before. One of the novel peptides was naturally processed and successfully induced HLAA2-restricted specific CTLs in both HLA transgenic mice and healthy donors. The method was useful, convenient and efficient for rapid identification of CTL epitopes derived from SARS-CoV proteins and will be possibly applicable for other pathogens to develop a peptide-based vaccine.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20378004</PMID><DateCompleted><Year>2010</Year><Month>05</Month><Day>12</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0394-6320</ISSN><JournalIssue CitedMedium="Print"><Volume>23</Volume><Issue>1</Issue><PubDate><MedlineDate>2010 Jan-Mar</MedlineDate></PubDate></JournalIssue><Title>International journal of immunopathology and pharmacology</Title><ISOAbbreviation>Int J Immunopathol Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Identification of SARS-COV spike protein-derived and HLA-A2-restricted human CTL epitopes by using a new muramyl dipeptidederivative adjuvant.</ArticleTitle><Pagination><MedlinePgn>165-77</MedlinePgn></Pagination><Abstract><AbstractText>Severe acute respiratory syndrome (SARS) spread during the winter of 2003, and attempts have been made to develop vaccines against SARS corona virus (SARS-CoV). The present study provides a strategy to rapidly identify SARS-CoV-derived antigenic peptides recognized by HLA-A2-restricted cytotoxic T lymphocytes (CTLs). Forty-three candidate peptides having HLA-A2-binding motifs were selected in silico and HLA-A2/Db chimeric MHC class I-transgenic mice were immunized with these peptides and a new derivative of muramyl dipeptide that can induce upregulation of HLA-DR, CD80, CD86, and CD40 in human CD14+ antigen presenting cells, was administered as an adjuvant. Six HLAA2-restricted mouse CTL epitopes were identified, including two new epitopes which have never been reported before. One of the novel peptides was naturally processed and successfully induced HLAA2-restricted specific CTLs in both HLA transgenic mice and healthy donors. The method was useful, convenient and efficient for rapid identification of CTL epitopes derived from SARS-CoV proteins and will be possibly applicable for other pathogens to develop a peptide-based vaccine.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Y-Z</ForeName><Initials>YZ</Initials><AffiliationInfo><Affiliation>Department of Immunogenetics, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Senju</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Q</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Irie</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Haruta</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Matsui</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Yasui</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Kohara</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Nishimura</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01AI061092</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Immunopathol Pharmacol</MedlineTA><NlmUniqueID>8911335</NlmUniqueID><ISSNLinking>0394-6320</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018984">Epitopes, T-Lymphocyte</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015789">HLA-A2 Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>53678-77-6</RegistryNumber><NameOfSubstance UI="D000119">Acetylmuramyl-Alanyl-Isoglutamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000119" MajorTopicYN="N">Acetylmuramyl-Alanyl-Isoglutamine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017951" MajorTopicYN="N">Antigen Presentation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018984" MajorTopicYN="N">Epitopes, T-Lymphocyte</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015789" MajorTopicYN="N">HLA-A2 Antigen</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013602" MajorTopicYN="N">T-Lymphocytes, Cytotoxic</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20378004</ArticleId><ArticleId IdType="pii">15</ArticleId><ArticleId IdType="doi">10.1177/039463201002300115</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000679 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000679 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:20378004
|texte= Identification of SARS-COV spike protein-derived and HLA-A2-restricted human CTL epitopes by using a new muramyl dipeptidederivative adjuvant.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:20378004" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a CovidV1
| This area was generated with Dilib version V0.6.33. |  |